PharmaLex with its own panel at Biotech Atelier 2021 Conference
The Bulgarian office provides PharmaLex with cost-effective access to highly qualified EU expertise
Friedrichsdorf / Sofia, March 21th 2017: As of 1st of March, 2017, the PharmaLex Group, a leading specialist provider of development consulting and scientific affairs, regulatory affairs and pharmacovigilance, has expanded its service portfolio in Bulgaria.
The Bulgarian office has existing dedicated pharmacovigilance expertise. With additional investment from the PharmaLex Group, the office will now be able to offer development consulting and scientific affairs as well as regulatory affairs services. These new service offerings will allow PharmaLex Bulgaria to build its customer base within the Eastern European region, whilst ensuring it is able to provide cost-effective services to a wider network of PharmaLex clients.
“There are compelling advantages to strengthening our service portfolio in Bulgaria”, explained Dr. Thomas Dobmeyer, CEO PharmaLex. “We are able to provide a high level of expertise at a very competitive rate”, he continued. Dr. Tilo Netzer, CEO PharmaLex, added, “Bulgaria has excellent potential for growth. With the further development of this office, we are able to offer competitive cost models and as they are located within the European Union, we can ensure high standards are maintained”. “We are delighted to further strengthen our presence in Central and Eastern Europe” said Albena Eftenova, Managing Director, PharmaLex Bulgaria. “This way we can ensure a closer collaboration with our regional customers, and by working together with the PharmaLex affiliates we will be able to service customers worldwide”, she added.
The PharmaLex Group now has over 500 employees, with 25 offices in 14 countries and more than 600 satisfied clients worldwide.
-Ends-
About PharmaLex <Confidence beyond compliance>:
PharmaLex combines local expertise with global reach in the area of development consulting and scientific services, regulatory affairs and pharmacovigilance. A proven track record of success in outsourcing programs, more than 25,000 successfully completed projects for over 600 clients worldwide, as well as extensive experience in all therapeutic areas and product groups, including advanced therapy medicinal products and biopharmaceuticals, medical and borderline products and alternative therapeutic approaches.
For further information, please contact:
Ms. Eva Keck
Director Business Development Operations, PharmaLex GmbH
eva.keck@pharmalex.com
+49 621 18 15 38 0 Harrlachweg 6; 68163 Mannheim, Germany
Related posts
